On the second question about a new drug coming in and a person taking many drugs, that can happen. Clinical trials don't always tell us how the therapies will react together.
I think one of the big promises from the proposals is the institutional reporting, because as patients go in and they're taking a number of medications, seeing that very early is very important, so if there is a reaction between a new drug coming out and other drugs that are already out there, we can try to pick that up. The quality of reporting could increase in that environment.
Right now, if you get an adverse reaction and then you look at it, the patient could be on four or five drugs, and have a number of medical conditions. It's hard, looking at that, to tell what happened. These new powers of being able to follow up and really study and verify and to do it in a disciplined way is really what we're trying to move through in Vanessa's law.